CAMBRIDGE, MA, Beacon Therapeutics has raised $170M in Series B funding led by Forbion.
Beacon Therapeutics has raised $170M in Series B funding led by Forbion alongside existing investors Syncona and Oxford Science Enterprises, as well as new investors TCGX and Advent Life Sciences.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
